Abeona Therapeutics Inc. (ABEO)

Market Cap	342.25M +2.0%
Revenue (ttm)	25.52M +6,280.0%
Net Income	-62.89M
EPS	-1.18
Shares Out	57.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,445,166
Open	6.21
Previous Close	6.35
Day's Range	5.82 - 6.29
52-Week Range	4.00 - 7.65
Beta	1.34
Analysts	Strong Buy
Price Target	18.86 (+215.12%)
Earnings Date	Aug 13, 2026

About ABEO

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 19, 1980
• Employees: 226
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO
• Website: https://www.abeonatherapeutics.com

Analyst Summary

According to 6 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $18.86, which is an increase of 215.12% from the latest price.

Price Target

$18.86

(215.12% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 15, 2026

Data Sources Report a data error